Melanoma Clinical Trial

A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

Summary

The purpose of this study is to evaluate two different dose combinations of nivolumab and ipilimumab in the treatment of melanoma.

View Eligibility Criteria

Eligibility Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

Subject must have been diagnosed with stage III or/and stage IV histologically confirmed melanoma [per American Joint Committee on Cancer (AJCC) staging system] that is unresectable or metastatic
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
Subject has not been treated by systemic anticancer therapy for unresectable or metastatic melanoma

Exclusion Criteria:

Subjects with active brain metastases or leptomeningeal metastases
Subjects with ocular melanoma
Subjects with active, known or suspected autoimmune disease

Other protocol defined inclusion/exclusion criteria could apply

Study is for people with:

Melanoma

Phase:

Phase 3

Estimated Enrollment:

387

Study ID:

NCT02714218

Recruitment Status:

Completed

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 57 Locations for this study

See Locations Near You

University Of Colorado Cancer Center
Aurora Colorado, 80045, United States
H. Lee Moffitt Cancer Center
Tampa Florida, 33612, United States
Allina Health
Fridley Minnesota, 55432, United States
Washington University School Of Medicine
Saint Louis Missouri, 63110, United States
Comprehensive Cancer Centers of Nevada
Las Vegas Nevada, 89148, United States
Dartmouth-Hitchcock Medical Center
Lebanon New Hampshire, 03756, United States
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack New Jersey, 07601, United States
Levine Cancer Institute
Charlotte North Carolina, 28204, United States
Lehigh Valley Health Network
Allentown Pennsylvania, 18103, United States
University Of Virginia Health System
Charlottesville Virginia, 22908, United States
University of Washington - Seattle Cancer Care Alliance
Seattle Washington, 98109, United States
Local Institution
North Sydney New South Wales, 2060, Australia
Local Institution - 0045
Waratah New South Wales, 2298, Australia
Local Institution
Greenslopes Queensland, 4120, Australia
Local Institution
Melbourne Victoria, 3004, Australia
Local Institution - 0007
Edmonton Alberta, T6G 1, Canada
Princess Margaret Cancer Centre
Toronto Ontario, M5G 2, Canada
CHU de Quebec - Universite Laval
Quebec , G1R 2, Canada
Local Institution - 0063
Aarhus N , 8200, Denmark
Local Institution - 0065
Herlev , 2730, Denmark
Local Institution - 0064
Odense , 5000, Denmark
Hopital Saint Andre
Bordeaux , 33075, France
Chru De Lille
Lille , 59037, France
Hopital De La Timone
Marseille Cedex 5 , 13385, France
Hopital Hotel Dieu
Nantes Cedex , 44093, France
Hopital Saint Louis
Paris , 75475, France
Centre Hospitalier Lyon Sud
Pierre Benite , 69310, France
Institut Claudius Regaud
Toulouse Cedex 9 , 31059, France
Local Institution - 0019
Villejuif , 94805, France
Universitaetsklinikum Essen
Essen , 45147, Germany
Universitaetsklinikum Heidelberg
Heidelberg , 69120, Germany
Ludwig-Maximilians-Universitaet
Muenchen , 80337, Germany
Universitaetsklinikum Tuebingen
Tuebingen , 72076, Germany
Local Institution
Ramat Gan , 52621, Israel
Local Institution - 0039
Bergamo , 24127, Italy
Local Institution - 0042
Milano , 20133, Italy
Local Institution - 0040
Napoli , 80131, Italy
Istituto Oncologico Veneto IOV
Padova , 35128, Italy
Local Institution - 0041
Siena , 53100, Italy
Ospedale San Vincenzo
Taormina , 98039, Italy
Local Institution - 0052
Amsterdam , 1066 , Netherlands
Local Institution
Amsterdam , 1081 , Netherlands
University Medical Center Groningen (Umcg)
Groningen , 9700R, Netherlands
Uniwersyteckie Centrum Kliniczne Klinika Onkologii I Radiote
Gdansk , 80-21, Poland
Klinika Nowotworow Ukladowych i Uogolnionych
Krakow , 31-11, Poland
Klinika Nowotworow Tkanek Miekkich, Kosci i Czerniakow
Warszawa , 02-78, Poland
Local Institution
Moscow , 11547, Russian Federation
Local Institution
Badalona-barcelona , 08916, Spain
Local Institution - 0024
Barcelona , 08036, Spain
Local Institution
Madrid , 28007, Spain
Local Institution - 0027
Madrid , 28034, Spain
Local Institution
San Sabastian Gipuzkoa , 20014, Spain
Local Institution
Valencia , 46014, Spain
Local Institution
Manchester Greater Manchester, M20 4, United Kingdom
Local Institution
Oxford Oxfordshire, OX3 7, United Kingdom
Local Institution
Guildford , GU2 7, United Kingdom
Local Institution
London , SW3 6, United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Melanoma

Phase:

Phase 3

Estimated Enrollment:

387

Study ID:

NCT02714218

Recruitment Status:

Completed

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider